JP2009542608A - 医薬組合せ剤 - Google Patents

Info

Publication number

JP2009542608A

JP2009542608A JP2009517403A JP2009517403A JP2009542608A JP 2009542608 A JP2009542608 A JP 2009542608A JP 2009517403 A JP2009517403 A JP 2009517403A JP 2009517403 A JP2009517403 A JP 2009517403A JP 2009542608 A JP2009542608 A JP 2009542608A

Authority

JP

Japan

Prior art keywords

acid

compound

group

formula

kinase

Prior art date

2006-06-29

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 claims abstract description 236
• 238000011282 treatment Methods 0.000 claims abstract description 150
• 206010028980 Neoplasm Diseases 0.000 claims abstract description 135
• 238000000034 method Methods 0.000 claims abstract description 101
• 201000011510 cancer Diseases 0.000 claims abstract description 94
• 239000000126 substance Substances 0.000 claims abstract description 7
• -1 amino, methylamino, methyl Chemical group 0.000 claims description 148
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 123
• 201000010099 disease Diseases 0.000 claims description 116
• 230000035772 mutation Effects 0.000 claims description 99
• 150000003839 salts Chemical class 0.000 claims description 85
• 239000001257 hydrogen Substances 0.000 claims description 78
• 229910052739 hydrogen Inorganic materials 0.000 claims description 78
• 108091000080 Phosphotransferase Proteins 0.000 claims description 71
• 102000020233 phosphotransferase Human genes 0.000 claims description 71
• 210000004027 cell Anatomy 0.000 claims description 70
• 230000002265 prevention Effects 0.000 claims description 69
• 230000000694 effects Effects 0.000 claims description 68
• 239000003814 drug Substances 0.000 claims description 66
• 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 claims description 61
• 125000000217 alkyl group Chemical group 0.000 claims description 61
• 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims description 60
• 125000000623 heterocyclic group Chemical group 0.000 claims description 60
• 108090000623 proteins and genes Proteins 0.000 claims description 58
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 57
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 55
• 125000001183 hydrocarbyl group Chemical group 0.000 claims description 53
• 241000124008 Mammalia Species 0.000 claims description 52
• 125000003545 alkoxy group Chemical group 0.000 claims description 52
• 239000003112 inhibitor Substances 0.000 claims description 51
• 102000003989 Aurora kinases Human genes 0.000 claims description 50
• 108090000433 Aurora kinases Proteins 0.000 claims description 50
• 102000003903 Cyclin-dependent kinases Human genes 0.000 claims description 47
• 108090000266 Cyclin-dependent kinases Proteins 0.000 claims description 47
• 229910052736 halogen Inorganic materials 0.000 claims description 47
• 150000002367 halogens Chemical class 0.000 claims description 47
• 239000002253 acid Substances 0.000 claims description 46
• 229910052760 oxygen Inorganic materials 0.000 claims description 43
• 239000011737 fluorine Substances 0.000 claims description 42
• 229910052731 fluorine Inorganic materials 0.000 claims description 42
• 125000001424 substituent group Chemical group 0.000 claims description 42
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 40
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 39
• 230000003827 upregulation Effects 0.000 claims description 36
• 108090000461 Aurora Kinase A Proteins 0.000 claims description 35
• 229910005965 SO 2 Inorganic materials 0.000 claims description 34
• 230000002159 abnormal effect Effects 0.000 claims description 33
• 238000004519 manufacturing process Methods 0.000 claims description 32
• 125000002837 carbocyclic group Chemical group 0.000 claims description 31
• 230000001404 mediated effect Effects 0.000 claims description 31
• 102000004000 Aurora Kinase A Human genes 0.000 claims description 30
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 30
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 30
• 229910052717 sulfur Inorganic materials 0.000 claims description 30
• 239000013078 crystal Substances 0.000 claims description 28
• 230000002401 inhibitory effect Effects 0.000 claims description 26
• 230000005764 inhibitory process Effects 0.000 claims description 25
• 108090000749 Aurora kinase B Proteins 0.000 claims description 23
• 102000004228 Aurora kinase B Human genes 0.000 claims description 22
• 238000002405 diagnostic procedure Methods 0.000 claims description 22
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 22
• 230000010261 cell growth Effects 0.000 claims description 21
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 20
• 101150073031 cdk2 gene Proteins 0.000 claims description 20
• 239000000460 chlorine Substances 0.000 claims description 19
• 229910052801 chlorine Inorganic materials 0.000 claims description 19
• 230000037361 pathway Effects 0.000 claims description 19
• 125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 19
• 150000001204 N-oxides Chemical class 0.000 claims description 18
• 230000027455 binding Effects 0.000 claims description 18
• 125000004432 carbon atom Chemical group C* 0.000 claims description 18
• 125000005842 heteroatom Chemical group 0.000 claims description 18
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 18
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 17
• JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical group C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims description 17
• 230000004663 cell proliferation Effects 0.000 claims description 17
• 230000001965 increasing effect Effects 0.000 claims description 17
• 229940116871 l-lactate Drugs 0.000 claims description 17
• 230000004044 response Effects 0.000 claims description 17
• 239000012453 solvate Chemical class 0.000 claims description 17
• 239000003795 chemical substances by application Substances 0.000 claims description 16
• 229940079593 drug Drugs 0.000 claims description 16
• 239000008194 pharmaceutical composition Substances 0.000 claims description 16
• 230000011664 signaling Effects 0.000 claims description 16
• 108091007914 CDKs Proteins 0.000 claims description 15
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 15
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 15
• 102000003909 Cyclin E Human genes 0.000 claims description 14
• 108090000257 Cyclin E Proteins 0.000 claims description 14
• 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 claims description 13
• 101150012716 CDK1 gene Proteins 0.000 claims description 12
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 12
• 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 claims description 12
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 12
• QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 claims description 12
• WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 12
• 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 12
• 238000002648 combination therapy Methods 0.000 claims description 12
• 125000004663 dialkyl amino group Chemical group 0.000 claims description 12
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 12
• CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims description 12
• LOLPPWBBNUVNQZ-UHFFFAOYSA-N chembl495727 Chemical compound C=1NN=C(C=2NC3=CC=C(CN4CCOCC4)C=C3N=2)C=1NC(=O)NC1CC1 LOLPPWBBNUVNQZ-UHFFFAOYSA-N 0.000 claims description 11
• 230000001419 dependent effect Effects 0.000 claims description 11
• 239000000203 mixture Substances 0.000 claims description 11
• 229910052757 nitrogen Inorganic materials 0.000 claims description 11
• 238000000634 powder X-ray diffraction Methods 0.000 claims description 11
• 229930000044 secondary metabolite Natural products 0.000 claims description 11
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 10
• 230000015572 biosynthetic process Effects 0.000 claims description 10
• 239000002875 cyclin dependent kinase inhibitor Substances 0.000 claims description 10
• AQYSYJUIMQTRMV-UHFFFAOYSA-N hypofluorous acid Chemical group FO AQYSYJUIMQTRMV-UHFFFAOYSA-N 0.000 claims description 10
• 239000008267 milk Substances 0.000 claims description 10
• OVPNQJVDAFNBDN-UHFFFAOYSA-N 4-(2,6-dichlorobenzamido)-N-(piperidin-4-yl)-pyrazole-3-carboxamide Chemical compound ClC1=CC=CC(Cl)=C1C(=O)NC1=CNN=C1C(=O)NC1CCNCC1 OVPNQJVDAFNBDN-UHFFFAOYSA-N 0.000 claims description 9
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 9
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 9
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 9
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 9
• 239000005441 aurora Substances 0.000 claims description 9
• POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 claims description 9
• 125000001153 fluoro group Chemical group F* 0.000 claims description 9
• 230000009467 reduction Effects 0.000 claims description 9
• 230000008685 targeting Effects 0.000 claims description 9
• WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 claims description 8
• RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 8
• ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 8
• AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 8
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 8
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 8
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 8
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 8
• 229960002448 dasatinib Drugs 0.000 claims description 8
• GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 8
• IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 8
• KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 claims description 8
• XTEGVFVZDVNBPF-UHFFFAOYSA-N naphthalene-1,5-disulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1S(O)(=O)=O XTEGVFVZDVNBPF-UHFFFAOYSA-N 0.000 claims description 8
• HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims description 8
• PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims description 8
• ZMZDMBWJUHKJPS-UHFFFAOYSA-N thiocyanic acid Chemical compound SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 claims description 8
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
• 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 7
• 239000005536 L01XE08 - Nilotinib Substances 0.000 claims description 7
• 235000011054 acetic acid Nutrition 0.000 claims description 7
• 125000003282 alkyl amino group Chemical group 0.000 claims description 7
• 229940100198 alkylating agent Drugs 0.000 claims description 7
• 239000002168 alkylating agent Substances 0.000 claims description 7
• 125000002947 alkylene group Chemical group 0.000 claims description 7
• 125000004429 atom Chemical group 0.000 claims description 7
• 230000032823 cell division Effects 0.000 claims description 7
• 229960000390 fludarabine Drugs 0.000 claims description 7
• GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 7
• 229960001346 nilotinib Drugs 0.000 claims description 7
• 239000000047 product Substances 0.000 claims description 7
• DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims description 6
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 6
• KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 claims description 6
• CCUXEBOOTMDSAM-UHFFFAOYSA-N 4-[(2,6-dichlorobenzoyl)amino]-n-(1-methylsulfonylpiperidin-4-yl)-1h-pyrazole-5-carboxamide Chemical compound C1CN(S(=O)(=O)C)CCC1NC(=O)C1=C(NC(=O)C=2C(=CC=CC=2Cl)Cl)C=NN1 CCUXEBOOTMDSAM-UHFFFAOYSA-N 0.000 claims description 6
• 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 6
• RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 6
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 6
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 6
• 239000001361 adipic acid Substances 0.000 claims description 6
• 235000011037 adipic acid Nutrition 0.000 claims description 6
• 229960005261 aspartic acid Drugs 0.000 claims description 6
• 239000004202 carbamide Substances 0.000 claims description 6
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
• XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 6
• 235000012208 gluconic acid Nutrition 0.000 claims description 6
• 229950006191 gluconic acid Drugs 0.000 claims description 6
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 6
• 150000002500 ions Chemical class 0.000 claims description 6
• SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 claims description 6
• 239000011975 tartaric acid Substances 0.000 claims description 6
• 235000002906 tartaric acid Nutrition 0.000 claims description 6
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 6
• NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 6
• 102000004127 Cytokines Human genes 0.000 claims description 5
• 108090000695 Cytokines Proteins 0.000 claims description 5
• 235000021355 Stearic acid Nutrition 0.000 claims description 5
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 5
• 230000033077 cellular process Effects 0.000 claims description 5
• 238000001990 intravenous administration Methods 0.000 claims description 5
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
• 229940098779 methanesulfonic acid Drugs 0.000 claims description 5
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 5
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 5
• 239000008117 stearic acid Substances 0.000 claims description 5
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 5
• 230000004614 tumor growth Effects 0.000 claims description 5
• WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 4
• LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 claims description 4
• SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical group C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 claims description 4
• 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 4
• 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 4
• LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 4
• 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 4
• 125000001054 5 membered carbocyclic group Chemical group 0.000 claims description 4
• QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 4
• 239000005711 Benzoic acid Substances 0.000 claims description 4
• 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 4
• 241000723346 Cinnamomum camphora Species 0.000 claims description 4
• CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 4
• 230000005778 DNA damage Effects 0.000 claims description 4
• 231100000277 DNA damage Toxicity 0.000 claims description 4
• AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 4
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
• DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 claims description 4
• CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 4
• 229930182816 L-glutamine Natural products 0.000 claims description 4
• 241001465754 Metazoa Species 0.000 claims description 4
• DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 4
• 239000005642 Oleic acid Substances 0.000 claims description 4
• ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 4
• 235000021314 Palmitic acid Nutrition 0.000 claims description 4
• 206010070834 Sensitisation Diseases 0.000 claims description 4
• 235000010443 alginic acid Nutrition 0.000 claims description 4
• 229920000615 alginic acid Polymers 0.000 claims description 4
• 239000000783 alginic acid Substances 0.000 claims description 4
• 229960001126 alginic acid Drugs 0.000 claims description 4
• 150000004781 alginic acids Chemical class 0.000 claims description 4
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 4
• 125000003118 aryl group Chemical group 0.000 claims description 4
• 235000010233 benzoic acid Nutrition 0.000 claims description 4
• 229930008380 camphor Natural products 0.000 claims description 4
• 229960000846 camphor Drugs 0.000 claims description 4
• BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 4
• 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 claims description 4
• HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims description 4
• MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 claims description 4
• 229940043264 dodecyl sulfate Drugs 0.000 claims description 4
• CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims description 4
• DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 claims description 4
• XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 4
• 229960005219 gentisic acid Drugs 0.000 claims description 4
• 239000008103 glucose Substances 0.000 claims description 4
• QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 4
• WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 4
• 239000011664 nicotinic acid Substances 0.000 claims description 4
• 235000001968 nicotinic acid Nutrition 0.000 claims description 4
• 229960003512 nicotinic acid Drugs 0.000 claims description 4
• WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 4
• ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 4
• 229960002969 oleic acid Drugs 0.000 claims description 4
• 229960005010 orotic acid Drugs 0.000 claims description 4
• WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 claims description 4
• WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 claims description 4
• 230000008313 sensitization Effects 0.000 claims description 4
• 125000004562 2,3-dihydroindol-1-yl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 3
• 125000004215 2,4-difluorophenyl group Chemical group [H]C1=C([H])C(*)=C(F)C([H])=C1F 0.000 claims description 3
• 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 3
• 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 claims description 3
• UMZCLZPXPCNKML-UHFFFAOYSA-N 2h-imidazo[4,5-d][1,3]thiazole Chemical group C1=NC2=NCSC2=N1 UMZCLZPXPCNKML-UHFFFAOYSA-N 0.000 claims description 3
• 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims description 3
• UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 claims description 3
• 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 3
• 125000004487 4-tetrahydropyranyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
• MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 3
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
• UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 claims description 3
• IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 3
• 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 3
• 239000005551 L01XE03 - Erlotinib Substances 0.000 claims description 3
• 229930012538 Paclitaxel Natural products 0.000 claims description 3
• 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
• SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 3
• 229940092714 benzenesulfonic acid Drugs 0.000 claims description 3
• 229960004365 benzoic acid Drugs 0.000 claims description 3
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 3
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
• AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims description 3
• 229960001433 erlotinib Drugs 0.000 claims description 3
• AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 claims description 3
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 3
• MDQRDWAGHRLBPA-UHFFFAOYSA-N fluoroamine Chemical compound FN MDQRDWAGHRLBPA-UHFFFAOYSA-N 0.000 claims description 3
• 238000009472 formulation Methods 0.000 claims description 3
• 229960002584 gefitinib Drugs 0.000 claims description 3
• 125000001072 heteroaryl group Chemical group 0.000 claims description 3
• RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical class OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 claims description 3
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 3
• 229960003685 imatinib mesylate Drugs 0.000 claims description 3
• 238000002329 infrared spectrum Methods 0.000 claims description 3
• 229960004768 irinotecan Drugs 0.000 claims description 3
• 229940045996 isethionic acid Drugs 0.000 claims description 3
• 229940099563 lactobionic acid Drugs 0.000 claims description 3
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
• 239000011976 maleic acid Substances 0.000 claims description 3
• 229940099690 malic acid Drugs 0.000 claims description 3
• 239000001630 malic acid Substances 0.000 claims description 3
• 235000011090 malic acid Nutrition 0.000 claims description 3
• 239000003550 marker Substances 0.000 claims description 3
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 3
• 235000013336 milk Nutrition 0.000 claims description 3
• 210000004080 milk Anatomy 0.000 claims description 3
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 3
• KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 claims description 3
• 235000006408 oxalic acid Nutrition 0.000 claims description 3
• 229940116315 oxalic acid Drugs 0.000 claims description 3
• 229960001592 paclitaxel Drugs 0.000 claims description 3
• 229940098695 palmitic acid Drugs 0.000 claims description 3
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
• 230000001737 promoting effect Effects 0.000 claims description 3
• 238000011321 prophylaxis Methods 0.000 claims description 3
• 235000019260 propionic acid Nutrition 0.000 claims description 3
• 125000004940 pyridazin-4-yl group Chemical group N1=NC=C(C=C1)* 0.000 claims description 3
• IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 3
• 230000002829 reductive effect Effects 0.000 claims description 3
• 229920006395 saturated elastomer Polymers 0.000 claims description 3
• 235000000346 sugar Nutrition 0.000 claims description 3
• DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims description 3
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
• 238000012360 testing method Methods 0.000 claims description 3
• 239000008181 tonicity modifier Substances 0.000 claims description 3
• 229940005605 valeric acid Drugs 0.000 claims description 3
• LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 claims description 2
• FOMTWLBLESUJEU-UHFFFAOYSA-N 5-(piperidin-1-ylmethyl)furan-2-carboxylic acid Chemical compound O1C(C(=O)O)=CC=C1CN1CCCCC1 FOMTWLBLESUJEU-UHFFFAOYSA-N 0.000 claims description 2
• 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 2
• 230000004543 DNA replication Effects 0.000 claims description 2
• 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 2
• 102000029749 Microtubule Human genes 0.000 claims description 2
• 108091022875 Microtubule Proteins 0.000 claims description 2
• GOWJMLWLZVUCNC-UHFFFAOYSA-N N-[5-[6-(morpholin-4-ylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-yl]-2-oxo-1H-pyridine-3-carboxamide Chemical compound C=1C=CNC(=O)C=1C(=O)NC1=CNN=C1C(NC1=CC=2)=NC1=CC=2CN1CCOCC1 GOWJMLWLZVUCNC-UHFFFAOYSA-N 0.000 claims description 2
• AEMOLEFTQBMNLQ-WAXACMCWSA-N alpha-D-glucuronic acid Chemical compound O[C@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-WAXACMCWSA-N 0.000 claims description 2
• 230000000340 anti-metabolite Effects 0.000 claims description 2
• 229940100197 antimetabolite Drugs 0.000 claims description 2
• 239000002256 antimetabolite Substances 0.000 claims description 2
• 235000003704 aspartic acid Nutrition 0.000 claims description 2
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 2
• LSPHULWDVZXLIL-QUBYGPBYSA-N camphoric acid Chemical compound CC1(C)[C@H](C(O)=O)CC[C@]1(C)C(O)=O LSPHULWDVZXLIL-QUBYGPBYSA-N 0.000 claims description 2
• JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims description 2
• 229960004630 chlorambucil Drugs 0.000 claims description 2
• 229960004316 cisplatin Drugs 0.000 claims description 2
• DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 2
• 229960004397 cyclophosphamide Drugs 0.000 claims description 2
• 229960004679 doxorubicin Drugs 0.000 claims description 2
• 239000003937 drug carrier Substances 0.000 claims description 2
• 239000001530 fumaric acid Substances 0.000 claims description 2
• YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims description 2
• 229940043355 kinase inhibitor Drugs 0.000 claims description 2
• 150000002632 lipids Chemical class 0.000 claims description 2
• 239000012931 lyophilized formulation Substances 0.000 claims description 2
• 210000004688 microtubule Anatomy 0.000 claims description 2
• UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 2
• 235000005152 nicotinamide Nutrition 0.000 claims description 2
• 239000011570 nicotinamide Substances 0.000 claims description 2
• 229960003966 nicotinamide Drugs 0.000 claims description 2
• 229960002446 octanoic acid Drugs 0.000 claims description 2
• 230000036961 partial effect Effects 0.000 claims description 2
• 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 2
• 229960003787 sorafenib Drugs 0.000 claims description 2
• 230000020347 spindle assembly Effects 0.000 claims description 2
• 150000004886 thiomorpholines Chemical class 0.000 claims description 2
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims 11
• 150000002431 hydrogen Chemical class 0.000 claims 11
• 229940122803 Vinca alkaloid Drugs 0.000 claims 7
• 150000003058 platinum compounds Chemical class 0.000 claims 7
• KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 6
• 229940127093 camptothecin Drugs 0.000 claims 6
• VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 6
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 6
• 241001032544 Galearctus aurora Species 0.000 claims 5
• 229940123237 Taxane Drugs 0.000 claims 5
• 101710183280 Topoisomerase Proteins 0.000 claims 5
• 230000002280 anti-androgenic effect Effects 0.000 claims 5
• 239000000051 antiandrogen Substances 0.000 claims 5
• 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 5
• 239000003276 histone deacetylase inhibitor Substances 0.000 claims 5
• 125000002950 monocyclic group Chemical group 0.000 claims 5
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 4
• 102000010907 Cyclooxygenase 2 Human genes 0.000 claims 4
• 108010037462 Cyclooxygenase 2 Proteins 0.000 claims 4
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 4
• 101710160107 Outer membrane protein A Proteins 0.000 claims 4
• 239000007864 aqueous solution Substances 0.000 claims 4
• 229960001230 asparagine Drugs 0.000 claims 4
• 235000009582 asparagine Nutrition 0.000 claims 4
• VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 4
• 229960004562 carboplatin Drugs 0.000 claims 4
• 125000001309 chloro group Chemical group Cl* 0.000 claims 4
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 4
• BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 4
• 239000000243 solution Substances 0.000 claims 4
• DALBYNFQIAQTNZ-UHFFFAOYSA-N 1-(2,6-difluorophenyl)-1-[5-[6-(morpholin-4-ylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-yl]urea Chemical compound FC=1C=CC=C(F)C=1N(C(=O)N)C1=CNN=C1C(NC1=CC=2)=NC1=CC=2CN1CCOCC1 DALBYNFQIAQTNZ-UHFFFAOYSA-N 0.000 claims 3
• KDKUVYLMPJIGKA-UHFFFAOYSA-N 4-[[5-amino-1-[(2,6-difluorophenyl)-oxomethyl]-1,2,4-triazol-3-yl]amino]benzenesulfonamide Chemical compound N=1N(C(=O)C=2C(=CC=CC=2F)F)C(N)=NC=1NC1=CC=C(S(N)(=O)=O)C=C1 KDKUVYLMPJIGKA-UHFFFAOYSA-N 0.000 claims 3
• 230000007067 DNA methylation Effects 0.000 claims 3
• 229940079156 Proteasome inhibitor Drugs 0.000 claims 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Natural products CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 3
• 229930013356 epothilone Natural products 0.000 claims 3
• 239000007788 liquid Substances 0.000 claims 3
• 229960001756 oxaliplatin Drugs 0.000 claims 3
• DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 3
• 239000003207 proteasome inhibitor Substances 0.000 claims 3
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
• 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
• 229930007886 (R)-camphor Natural products 0.000 claims 2
• PFKFTWBEEFSNDU-UHFFFAOYSA-N 1,1'-Carbonyldiimidazole Substances C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims 2
• WJRRGYBTGDJBFX-UHFFFAOYSA-N 4-(2-methyl-3-propan-2-yl-4-imidazolyl)-N-(4-methylsulfonylphenyl)-2-pyrimidinamine Chemical compound CC(C)N1C(C)=NC=C1C1=CC=NC(NC=2C=CC(=CC=2)S(C)(=O)=O)=N1 WJRRGYBTGDJBFX-UHFFFAOYSA-N 0.000 claims 2
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 2
• UELIMKCXGLIYCY-UHFFFAOYSA-N 4-[(2,6-dichlorobenzoyl)amino]-n-piperidin-4-yl-1h-pyrazole-5-carboxamide;methanesulfonic acid Chemical compound CS(O)(=O)=O.ClC1=CC=CC(Cl)=C1C(=O)NC1=CNN=C1C(=O)NC1CCNCC1 UELIMKCXGLIYCY-UHFFFAOYSA-N 0.000 claims 2
• BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 claims 2
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims 2
• HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 claims 2
• AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical group OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 claims 2
• 230000033616 DNA repair Effects 0.000 claims 2
• GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
• 102000003688 G-Protein-Coupled Receptors Human genes 0.000 claims 2
• 108090000045 G-Protein-Coupled Receptors Proteins 0.000 claims 2
• 102000003964 Histone deacetylase Human genes 0.000 claims 2
• 108090000353 Histone deacetylase Proteins 0.000 claims 2
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
• OUSFTKFNBAZUKL-UHFFFAOYSA-N N-(5-{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl}-1,3-thiazol-2-yl)piperidine-4-carboxamide Chemical compound O1C(C(C)(C)C)=CN=C1CSC(S1)=CN=C1NC(=O)C1CCNCC1 OUSFTKFNBAZUKL-UHFFFAOYSA-N 0.000 claims 2
• UAOIPNOTWOYAMU-LBPRGKRZSA-N PHA-533533 Chemical compound O=C([C@@H](C)C=1C=CC(=CC=1)N1C(CCC1)=O)NC(=NN1)C=C1C1CC1 UAOIPNOTWOYAMU-LBPRGKRZSA-N 0.000 claims 2
• YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims 2
• NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
• NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 claims 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 2
• JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 2
• KMLCRELJHYKIIL-UHFFFAOYSA-N [1-(azanidylmethyl)cyclohexyl]methylazanide;platinum(2+);sulfuric acid Chemical compound [Pt+2].OS(O)(=O)=O.[NH-]CC1(C[NH-])CCCCC1 KMLCRELJHYKIIL-UHFFFAOYSA-N 0.000 claims 2
• XFEAVRUNILSQAP-UHFFFAOYSA-N [Pt].C(C)C(C(=O)ON)C(=O)ON Chemical compound [Pt].C(C)C(C(=O)ON)C(=O)ON XFEAVRUNILSQAP-UHFFFAOYSA-N 0.000 claims 2
• 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
• 229960003437 aminoglutethimide Drugs 0.000 claims 2
• ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 claims 2
• 229960002932 anastrozole Drugs 0.000 claims 2
• YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 claims 2
• 229960002938 bexarotene Drugs 0.000 claims 2
• 229960002092 busulfan Drugs 0.000 claims 2
• 239000006227 byproduct Substances 0.000 claims 2
• 229910052799 carbon Inorganic materials 0.000 claims 2
• 150000003883 epothilone derivatives Chemical class 0.000 claims 2
• VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical group COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 2
• 229960005420 etoposide Drugs 0.000 claims 2
• 229960000255 exemestane Drugs 0.000 claims 2
• 229960002949 fluorouracil Drugs 0.000 claims 2
• 235000019253 formic acid Nutrition 0.000 claims 2
• 239000000174 gluconic acid Substances 0.000 claims 2
• 238000010438 heat treatment Methods 0.000 claims 2
• 230000028993 immune response Effects 0.000 claims 2
• 238000002347 injection Methods 0.000 claims 2
• 239000007924 injection Substances 0.000 claims 2
• 229950010897 iproplatin Drugs 0.000 claims 2
• UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 2
• 229960003881 letrozole Drugs 0.000 claims 2
• HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims 2
• 229960000485 methotrexate Drugs 0.000 claims 2
• 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 2
• 239000002777 nucleoside Chemical class 0.000 claims 2
• 150000003833 nucleoside derivatives Chemical class 0.000 claims 2
• 125000004043 oxo group Chemical group O=* 0.000 claims 2
• HRGDZIGMBDGFTC-UHFFFAOYSA-N platinum(2+) Chemical compound [Pt+2] HRGDZIGMBDGFTC-UHFFFAOYSA-N 0.000 claims 2
• 239000002904 solvent Substances 0.000 claims 2
• 229950004330 spiroplatin Drugs 0.000 claims 2
• 229960000303 topotecan Drugs 0.000 claims 2
• UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 2
• 229960003048 vinblastine Drugs 0.000 claims 2
• JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 2
• 229960004528 vincristine Drugs 0.000 claims 2
• OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 2
• OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 2
• GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 2
• 229960002066 vinorelbine Drugs 0.000 claims 2
• 125000004769 (C1-C4) alkylsulfonyl group Chemical group 0.000 claims 1
• 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
• LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 claims 1
• BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 claims 1
• RWYNKTMXFIMBFE-WNQIDUERSA-N 1-cyclopropyl-3-[5-[6-(morpholin-4-ylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-yl]urea (2S)-2-hydroxypropanoic acid Chemical compound C[C@H](O)C(O)=O.C=1NN=C(C=2NC3=CC=C(CN4CCOCC4)C=C3N=2)C=1NC(=O)NC1CC1 RWYNKTMXFIMBFE-WNQIDUERSA-N 0.000 claims 1
• RWYNKTMXFIMBFE-UHFFFAOYSA-N 1-cyclopropyl-3-[5-[6-(morpholin-4-ylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-yl]urea 2-hydroxypropanoic acid Chemical compound CC(O)C(O)=O.C=1NN=C(C=2NC3=CC=C(CN4CCOCC4)C=C3N=2)C=1NC(=O)NC1CC1 RWYNKTMXFIMBFE-UHFFFAOYSA-N 0.000 claims 1
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 1
• 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 1
• 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
• AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 claims 1
• CXBHMSHVCKEEGW-UHFFFAOYSA-N 4-(2,6-difluorobenzamido)-N-(piperidin-4-yl)-1H-pyrazole-3-carboxamide Chemical compound FC1=CC=CC(F)=C1C(=O)NC1=CNN=C1C(=O)NC1CCNCC1 CXBHMSHVCKEEGW-UHFFFAOYSA-N 0.000 claims 1
• BRZQYVXJAZMSBB-UHFFFAOYSA-N 4-[(2,6-dichlorobenzoyl)amino]-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C1=NNC=C1NC(=O)C1=C(Cl)C=CC=C1Cl BRZQYVXJAZMSBB-UHFFFAOYSA-N 0.000 claims 1
• UWANMJIXIZUGCE-UHFFFAOYSA-N 4-[(2,6-difluorobenzoyl)amino]-n-(1-methylpiperidin-4-yl)-1h-pyrazole-5-carboxamide Chemical compound C1CN(C)CCC1NC(=O)C1=NNC=C1NC(=O)C1=C(F)C=CC=C1F UWANMJIXIZUGCE-UHFFFAOYSA-N 0.000 claims 1
• GEJVJGWDUTWXOU-UHFFFAOYSA-N 4-[(2-fluoro-6-methoxybenzoyl)amino]-1h-pyrazole-5-carboxylic acid Chemical compound COC1=CC=CC(F)=C1C(=O)NC1=C(C(O)=O)NN=C1 GEJVJGWDUTWXOU-UHFFFAOYSA-N 0.000 claims 1
• NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims 1
• XCASTYYLIOUMKF-UHFFFAOYSA-N 5-[6-(morpholin-4-ylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-amine Chemical compound NC1=CNN=C1C1=NC2=CC(CN3CCOCC3)=CC=C2N1 XCASTYYLIOUMKF-UHFFFAOYSA-N 0.000 claims 1
• XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims 1
• NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 1
• STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
• PBCZSGKMGDDXIJ-XMCQDBRXSA-N 7-hydroxystaurosporine Chemical compound N([C@@H](O)C1=C2C3=CC=CC=C3N3C2=C24)C(=O)C1=C2C1=CC=CC=C1N4[C@@H]1C[C@@H](NC)[C@@H](OC)[C@@]3(C)O1 PBCZSGKMGDDXIJ-XMCQDBRXSA-N 0.000 claims 1
• PBCZSGKMGDDXIJ-UHFFFAOYSA-N 7beta-hydroxystaurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3C(O)NC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 PBCZSGKMGDDXIJ-UHFFFAOYSA-N 0.000 claims 1
• SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 claims 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
• 229940122815 Aromatase inhibitor Drugs 0.000 claims 1
• 102100038080 B-cell receptor CD22 Human genes 0.000 claims 1
• 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 1
• LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims 1
• 102000013135 CD52 Antigen Human genes 0.000 claims 1
• 108010065524 CD52 Antigen Proteins 0.000 claims 1
• GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 1
• GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 1
• DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical group ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 1
• 102100031065 Choline kinase alpha Human genes 0.000 claims 1
• UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
• RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims 1
• 208000006558 Dental Calculus Diseases 0.000 claims 1
• ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 claims 1
• HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 claims 1
• VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims 1
• 108091007911 GSKs Proteins 0.000 claims 1
• DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims 1
• 102000004103 Glycogen Synthase Kinases Human genes 0.000 claims 1
• NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical group C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 claims 1
• BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims 1
• 108010069236 Goserelin Proteins 0.000 claims 1
• 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 1
• 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 1
• 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
• XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 claims 1
• XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 claims 1
• 102000006992 Interferon-alpha Human genes 0.000 claims 1
• 108010047761 Interferon-alpha Proteins 0.000 claims 1
• 102000008070 Interferon-gamma Human genes 0.000 claims 1
• 108010074328 Interferon-gamma Proteins 0.000 claims 1
• 102000014150 Interferons Human genes 0.000 claims 1
• 108010050904 Interferons Proteins 0.000 claims 1
• 102000000588 Interleukin-2 Human genes 0.000 claims 1
• 108010002350 Interleukin-2 Proteins 0.000 claims 1
• 102000015696 Interleukins Human genes 0.000 claims 1
• 108010063738 Interleukins Proteins 0.000 claims 1
• 102000010638 Kinesin Human genes 0.000 claims 1
• 108010063296 Kinesin Proteins 0.000 claims 1
• 150000003895 L-lactate salts Chemical class 0.000 claims 1
• 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
• 239000002118 L01XE12 - Vandetanib Substances 0.000 claims 1
• 108010000817 Leuprolide Proteins 0.000 claims 1
• GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims 1
• 239000012359 Methanesulfonyl chloride Substances 0.000 claims 1
• 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
• HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 claims 1
• ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
• BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 1
• IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 claims 1
• SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 claims 1
• 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 1
• 239000012190 activator Substances 0.000 claims 1
• WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 claims 1
• IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 claims 1
• 229960001445 alitretinoin Drugs 0.000 claims 1
• 125000006242 amine protecting group Chemical group 0.000 claims 1
• 229940045799 anthracyclines and related substance Drugs 0.000 claims 1
• 229940046836 anti-estrogen Drugs 0.000 claims 1
• 230000001833 anti-estrogenic effect Effects 0.000 claims 1
• 230000001399 anti-metabolic effect Effects 0.000 claims 1
• 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 claims 1
• 239000000427 antigen Substances 0.000 claims 1
• 108091007433 antigens Proteins 0.000 claims 1
• 102000036639 antigens Human genes 0.000 claims 1
• 229940045696 antineoplastic drug podophyllotoxin derivative Drugs 0.000 claims 1
• 229940045985 antineoplastic platinum compound Drugs 0.000 claims 1
• 239000003886 aromatase inhibitor Substances 0.000 claims 1
• 229960002756 azacitidine Drugs 0.000 claims 1
• XTKDAFGWCDAMPY-UHFFFAOYSA-N azaperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCN(C=2N=CC=CC=2)CC1 XTKDAFGWCDAMPY-UHFFFAOYSA-N 0.000 claims 1
• NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 claims 1
• BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 claims 1
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
• 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
• 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 1
• 229960000397 bevacizumab Drugs 0.000 claims 1
• 229960000997 bicalutamide Drugs 0.000 claims 1
• 125000002619 bicyclic group Chemical group 0.000 claims 1
• 229960001467 bortezomib Drugs 0.000 claims 1
• GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 1
• 239000007853 buffer solution Substances 0.000 claims 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
• VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
• 229960004117 capecitabine Drugs 0.000 claims 1
• 229960005243 carmustine Drugs 0.000 claims 1
• 229960000590 celecoxib Drugs 0.000 claims 1
• RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
• 229960005395 cetuximab Drugs 0.000 claims 1
• PIQCTGMSNWUMAF-UHFFFAOYSA-N chembl522892 Chemical compound C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 PIQCTGMSNWUMAF-UHFFFAOYSA-N 0.000 claims 1
• 239000007795 chemical reaction product Substances 0.000 claims 1
• 239000007979 citrate buffer Substances 0.000 claims 1
• 230000008602 contraction Effects 0.000 claims 1
• 239000007822 coupling agent Substances 0.000 claims 1
• 229940111134 coxibs Drugs 0.000 claims 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
• SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 claims 1
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims 1
• 229960000684 cytarabine Drugs 0.000 claims 1
• 229960000975 daunorubicin Drugs 0.000 claims 1
• STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
• 229960003603 decitabine Drugs 0.000 claims 1
• 238000004090 dissolution Methods 0.000 claims 1
• 229960003668 docetaxel Drugs 0.000 claims 1
• 229950004203 droloxifene Drugs 0.000 claims 1
• 239000000839 emulsion Substances 0.000 claims 1
• 229960001904 epirubicin Drugs 0.000 claims 1
• 239000000328 estrogen antagonist Substances 0.000 claims 1
• QJZOIPFECDFUMS-UHFFFAOYSA-N ethane-1,2-disulfonic acid;ethanesulfonic acid Chemical compound CCS(O)(=O)=O.OS(=O)(=O)CCS(O)(=O)=O QJZOIPFECDFUMS-UHFFFAOYSA-N 0.000 claims 1
• CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 claims 1
• 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 1
• 230000001747 exhibiting effect Effects 0.000 claims 1
• 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 claims 1
• 229940013688 formic acid Drugs 0.000 claims 1
• 238000004108 freeze drying Methods 0.000 claims 1
• 229960002258 fulvestrant Drugs 0.000 claims 1
• 229960005277 gemcitabine Drugs 0.000 claims 1
• SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
• 229960000578 gemtuzumab Drugs 0.000 claims 1
• 229940097043 glucuronic acid Drugs 0.000 claims 1
• 229960002913 goserelin Drugs 0.000 claims 1
• 125000005059 halophenyl group Chemical group 0.000 claims 1
• 239000003481 heat shock protein 90 inhibitor Substances 0.000 claims 1
• 150000002402 hexoses Chemical class 0.000 claims 1
• NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims 1
• 229960000908 idarubicin Drugs 0.000 claims 1
• 229960001101 ifosfamide Drugs 0.000 claims 1
• HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical group ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
• 238000001802 infusion Methods 0.000 claims 1
• 229960003130 interferon gamma Drugs 0.000 claims 1
• 229940047124 interferons Drugs 0.000 claims 1
• 229940047122 interleukins Drugs 0.000 claims 1
• 229960004891 lapatinib Drugs 0.000 claims 1
• BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
• GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims 1
• 229960004338 leuprorelin Drugs 0.000 claims 1
• 229960002247 lomustine Drugs 0.000 claims 1
• 229960004961 mechlorethamine Drugs 0.000 claims 1
• HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical class ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 claims 1
• 229960004296 megestrol acetate Drugs 0.000 claims 1
• RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 claims 1
• QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims 1
• 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
• 239000011859 microparticle Substances 0.000 claims 1
• 229960001156 mitoxantrone Drugs 0.000 claims 1
• KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims 1
• 239000012023 mustard compounds‎ Substances 0.000 claims 1
• MUTBJZVSRNUIHA-UHFFFAOYSA-N n-hydroxy-2-(4-naphthalen-2-ylsulfonylpiperazin-1-yl)pyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NO)=CN=C1N1CCN(S(=O)(=O)C=2C=C3C=CC=CC3=CC=2)CC1 MUTBJZVSRNUIHA-UHFFFAOYSA-N 0.000 claims 1
• 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
• 239000002105 nanoparticle Substances 0.000 claims 1
• PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 claims 1
• 230000003472 neutralizing effect Effects 0.000 claims 1
• 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
• 239000003960 organic solvent Substances 0.000 claims 1
• 238000007911 parenteral administration Methods 0.000 claims 1
• 239000002245 particle Substances 0.000 claims 1
• 229960005079 pemetrexed Drugs 0.000 claims 1
• QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 1
• UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 1
• BCIIMDOZSUCSEN-UHFFFAOYSA-N piperidin-4-amine Chemical compound NC1CCNCC1 BCIIMDOZSUCSEN-UHFFFAOYSA-N 0.000 claims 1
• GZXVJRNJTCNEIL-UHFFFAOYSA-L platinum(2+);propanedioate Chemical compound [Pt+2].[O-]C(=O)CC([O-])=O GZXVJRNJTCNEIL-UHFFFAOYSA-L 0.000 claims 1
• YJGVMLPVUAXIQN-XVVDYKMHSA-N podophyllotoxin Chemical class COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 claims 1
• 239000003600 podophyllotoxin derivative Substances 0.000 claims 1
• 239000002770 polo like kinase inhibitor Substances 0.000 claims 1
• UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical group OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims 1
• 150000003254 radicals Chemical class 0.000 claims 1
• 229960004622 raloxifene Drugs 0.000 claims 1
• GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims 1
• 229960004432 raltitrexed Drugs 0.000 claims 1
• 239000000376 reactant Substances 0.000 claims 1
• 150000004492 retinoid derivatives Chemical class 0.000 claims 1
• 229960004641 rituximab Drugs 0.000 claims 1
• 238000007920 subcutaneous administration Methods 0.000 claims 1
• 239000001384 succinic acid Substances 0.000 claims 1
• 235000011044 succinic acid Nutrition 0.000 claims 1
• YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims 1
• 229960001603 tamoxifen Drugs 0.000 claims 1
• 229960004964 temozolomide Drugs 0.000 claims 1
• NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims 1
• 229960001278 teniposide Drugs 0.000 claims 1
• 229960005026 toremifene Drugs 0.000 claims 1
• XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims 1
• 229960005267 tositumomab Drugs 0.000 claims 1
• 229960000575 trastuzumab Drugs 0.000 claims 1
• 229960001727 tretinoin Drugs 0.000 claims 1
• UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 claims 1
• 229960000241 vandetanib Drugs 0.000 claims 1
• UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 1
• YCOYDOIWSSHVCK-UHFFFAOYSA-N vatalanib Chemical compound C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-N 0.000 claims 1
• 238000002360 preparation method Methods 0.000 abstract description 5
• 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 36
• 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 35
• 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 35
• 102000004169 proteins and genes Human genes 0.000 description 30
• 208000011580 syndromic disease Diseases 0.000 description 30
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 29
• 239000005517 L01XE01 - Imatinib Substances 0.000 description 28
• 229960002411 imatinib Drugs 0.000 description 28
• 235000018102 proteins Nutrition 0.000 description 28
• 230000026731 phosphorylation Effects 0.000 description 26
• 238000006366 phosphorylation reaction Methods 0.000 description 26
• 230000014509 gene expression Effects 0.000 description 25
• 230000033115 angiogenesis Effects 0.000 description 24
• 210000004214 philadelphia chromosome Anatomy 0.000 description 23
• 108010082078 3-Phosphoinositide-Dependent Protein Kinases Proteins 0.000 description 21
• 102000003737 3-Phosphoinositide-Dependent Protein Kinases Human genes 0.000 description 21
• 230000004913 activation Effects 0.000 description 21
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 20
• 102000001301 EGF receptor Human genes 0.000 description 20
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 20
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 20
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 20
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 20
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 20
• 108060006698 EGF receptor Proteins 0.000 description 19
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 19
• 206010073148 Multiple endocrine neoplasia type 2A Diseases 0.000 description 19
• 108091008611 Protein Kinase B Proteins 0.000 description 19
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 19
• 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 19
• 208000032839 leukemia Diseases 0.000 description 19
• 102000005962 receptors Human genes 0.000 description 19
• 108020003175 receptors Proteins 0.000 description 19
• 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 18
• 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 18
• 239000003446 ligand Substances 0.000 description 18
• 210000001519 tissue Anatomy 0.000 description 18
• WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 17
• 102000016736 Cyclin Human genes 0.000 description 17
• 108050006400 Cyclin Proteins 0.000 description 17
• 201000006850 Familial medullary thyroid carcinoma Diseases 0.000 description 17
• 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 description 17
• 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 16
• 208000037538 Myelomonocytic Juvenile Leukemia Diseases 0.000 description 15
• 230000002018 overexpression Effects 0.000 description 15
• 206010051747 multiple endocrine neoplasia Diseases 0.000 description 14
• 208000014767 Myeloproliferative disease Diseases 0.000 description 13
• 208000017733 acquired polycythemia vera Diseases 0.000 description 13
• 230000007246 mechanism Effects 0.000 description 13
• 208000037244 polycythemia vera Diseases 0.000 description 13
• 230000035755 proliferation Effects 0.000 description 13
• 239000000758 substrate Substances 0.000 description 13
• 208000032027 Essential Thrombocythemia Diseases 0.000 description 12
• 108010024121 Janus Kinases Proteins 0.000 description 12
• 102000015617 Janus Kinases Human genes 0.000 description 12
• 201000003793 Myelodysplastic syndrome Diseases 0.000 description 12
• 102000001253 Protein Kinase Human genes 0.000 description 12
• 206010038933 Retinopathy of prematurity Diseases 0.000 description 12
• 230000005856 abnormality Effects 0.000 description 12
• 101150113535 chek1 gene Proteins 0.000 description 12
• 108060006633 protein kinase Proteins 0.000 description 12
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 12
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 12
• 230000004083 survival effect Effects 0.000 description 12
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 11
• 101100220616 Caenorhabditis elegans chk-2 gene Proteins 0.000 description 11
• 108010055334 EphB2 Receptor Proteins 0.000 description 11
• 102100031968 Ephrin type-B receptor 2 Human genes 0.000 description 11
• 108091008794 FGF receptors Proteins 0.000 description 11
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 11
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 11
• 206010033701 Papillary thyroid cancer Diseases 0.000 description 11
• 230000022131 cell cycle Effects 0.000 description 11
• 102000012803 ephrin Human genes 0.000 description 11
• 108060002566 ephrin Proteins 0.000 description 11
• 229940126864 fibroblast growth factor Drugs 0.000 description 11
• 230000008569 process Effects 0.000 description 11
• 208000030045 thyroid gland papillary carcinoma Diseases 0.000 description 11
• 208000031261 Acute myeloid leukaemia Diseases 0.000 description 10
• 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 10
• 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 10
• 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 10
• 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 10
• 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 description 10
• 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 10
• 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 10
• 102100028286 Proto-oncogene tyrosine-protein kinase receptor Ret Human genes 0.000 description 10
• 230000006907 apoptotic process Effects 0.000 description 10
• 210000000481 breast Anatomy 0.000 description 10
• 238000011161 development Methods 0.000 description 10
• 230000018109 developmental process Effects 0.000 description 10
• 102000004632 fms-Like Tyrosine Kinase 3 Human genes 0.000 description 10
• 108010003374 fms-Like Tyrosine Kinase 3 Proteins 0.000 description 10
• 201000011066 hemangioma Diseases 0.000 description 10
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 9
• 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 9
• 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 9
• 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 9
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 9
• 208000024770 Thyroid neoplasm Diseases 0.000 description 9
• 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 9
• 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 9
• 230000006870 function Effects 0.000 description 9
• 230000036210 malignancy Effects 0.000 description 9
• 230000002062 proliferating effect Effects 0.000 description 9
• 201000009030 Carcinoma Diseases 0.000 description 8
• 102100031983 Ephrin type-B receptor 4 Human genes 0.000 description 8
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 8
• 208000034578 Multiple myelomas Diseases 0.000 description 8
• 208000033833 Myelomonocytic Chronic Leukemia Diseases 0.000 description 8
• 206010035226 Plasma cell myeloma Diseases 0.000 description 8
• 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 8
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 8
• 208000000208 Wet Macular Degeneration Diseases 0.000 description 8
• 210000000349 chromosome Anatomy 0.000 description 8
• 208000005017 glioblastoma Diseases 0.000 description 8
• 230000003834 intracellular effect Effects 0.000 description 8
• 208000002780 macular degeneration Diseases 0.000 description 8
• 206010028537 myelofibrosis Diseases 0.000 description 8
• 230000019491 signal transduction Effects 0.000 description 8
• 230000001225 therapeutic effect Effects 0.000 description 8
• BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 7
• 206010010539 Congenital megacolon Diseases 0.000 description 7
• 102000004190 Enzymes Human genes 0.000 description 7
• 108090000790 Enzymes Proteins 0.000 description 7
• 208000004592 Hirschsprung disease Diseases 0.000 description 7
• 208000009289 Jackson-Weiss syndrome Diseases 0.000 description 7
• 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 7
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 7
• 239000004473 Threonine Substances 0.000 description 7
• 208000035475 disorder Diseases 0.000 description 7
• 201000003914 endometrial carcinoma Diseases 0.000 description 7
• 229940088598 enzyme Drugs 0.000 description 7
• 230000012010 growth Effects 0.000 description 7
• 239000003102 growth factor Substances 0.000 description 7
• 208000014829 head and neck neoplasm Diseases 0.000 description 7
• 230000003211 malignant effect Effects 0.000 description 7
• 239000012071 phase Substances 0.000 description 7
• 208000003476 primary myelofibrosis Diseases 0.000 description 7
• 208000014190 scalp syndrome Diseases 0.000 description 7
• 230000012488 skeletal system development Effects 0.000 description 7
• 230000000638 stimulation Effects 0.000 description 7
• 201000002510 thyroid cancer Diseases 0.000 description 7
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 7
• 206010009944 Colon cancer Diseases 0.000 description 6
• 206010012689 Diabetic retinopathy Diseases 0.000 description 6
• 108091008815 Eph receptors Proteins 0.000 description 6
• 102100031982 Ephrin type-B receptor 3 Human genes 0.000 description 6
• 101001064458 Homo sapiens Ephrin type-B receptor 3 Proteins 0.000 description 6
• 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 6
• 206010027476 Metastases Diseases 0.000 description 6
• 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 6
• 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 6
• 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 6
• 206010038934 Retinopathy proliferative Diseases 0.000 description 6
• 208000013593 acute megakaryoblastic leukemia Diseases 0.000 description 6
• 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 6
• 206010064930 age-related macular degeneration Diseases 0.000 description 6
• 230000003321 amplification Effects 0.000 description 6
• 230000008901 benefit Effects 0.000 description 6
• 230000033228 biological regulation Effects 0.000 description 6
• 238000005755 formation reaction Methods 0.000 description 6
• 201000010536 head and neck cancer Diseases 0.000 description 6
• 230000003993 interaction Effects 0.000 description 6
• 230000000302 ischemic effect Effects 0.000 description 6
• 238000003199 nucleic acid amplification method Methods 0.000 description 6
• 238000011160 research Methods 0.000 description 6
• 229940124597 therapeutic agent Drugs 0.000 description 6
• 210000004881 tumor cell Anatomy 0.000 description 6
• ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 5
• 208000001333 Colorectal Neoplasms Diseases 0.000 description 5
• 108020004414 DNA Proteins 0.000 description 5
• 206010014733 Endometrial cancer Diseases 0.000 description 5
• 206010014759 Endometrial neoplasm Diseases 0.000 description 5
• 102000050554 Eph Family Receptors Human genes 0.000 description 5
• 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 5
• 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 5
• 201000008808 Fibrosarcoma Diseases 0.000 description 5
• 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 5
• 102000004877 Insulin Human genes 0.000 description 5
• 108090001061 Insulin Proteins 0.000 description 5
• 208000022873 Ocular disease Diseases 0.000 description 5
• 108700020796 Oncogene Proteins 0.000 description 5
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 5
• 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 5
• 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 5
• 230000018199 S phase Effects 0.000 description 5
• 101001117144 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) [Pyruvate dehydrogenase (acetyl-transferring)] kinase 1, mitochondrial Proteins 0.000 description 5
• 102000040945 Transcription factor Human genes 0.000 description 5
• 108091023040 Transcription factor Proteins 0.000 description 5
• 230000003213 activating effect Effects 0.000 description 5
• 235000001014 amino acid Nutrition 0.000 description 5
• 210000000170 cell membrane Anatomy 0.000 description 5
• 230000001684 chronic effect Effects 0.000 description 5
• 230000004069 differentiation Effects 0.000 description 5
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 5
• 230000002500 effect on skin Effects 0.000 description 5
• 210000002889 endothelial cell Anatomy 0.000 description 5
• 208000030533 eye disease Diseases 0.000 description 5
• 238000000338 in vitro Methods 0.000 description 5
• 229940125396 insulin Drugs 0.000 description 5
• 230000009401 metastasis Effects 0.000 description 5
• 108090000765 processed proteins & peptides Proteins 0.000 description 5
• 238000004393 prognosis Methods 0.000 description 5
• 102220197900 rs121913516 Human genes 0.000 description 5
• 238000013518 transcription Methods 0.000 description 5
• 230000035897 transcription Effects 0.000 description 5
• 230000007704 transition Effects 0.000 description 5
• 102100032311 Aurora kinase A Human genes 0.000 description 4
• 206010006187 Breast cancer Diseases 0.000 description 4
• 208000026310 Breast neoplasm Diseases 0.000 description 4
• 208000005623 Carcinogenesis Diseases 0.000 description 4
• 108010055155 EphA8 Receptor Proteins 0.000 description 4
• 102100021601 Ephrin type-A receptor 8 Human genes 0.000 description 4
• 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 4
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 4
• 206010016654 Fibrosis Diseases 0.000 description 4
• 230000004707 G1/S transition Effects 0.000 description 4
• 201000010915 Glioblastoma multiforme Diseases 0.000 description 4
• 108010001483 Glycogen Synthase Proteins 0.000 description 4
• 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 description 4
• 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 4
• 101150113453 Gsk3a gene Proteins 0.000 description 4
• 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 4
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 4
• 102100040243 Microtubule-associated protein tau Human genes 0.000 description 4
• 108091007960 PI3Ks Proteins 0.000 description 4
• 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 4
• 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 4
• 206010060862 Prostate cancer Diseases 0.000 description 4
• 108060006706 SRC Proteins 0.000 description 4
• 102000001332 SRC Human genes 0.000 description 4
• 229940024606 amino acid Drugs 0.000 description 4
• 150000001413 amino acids Chemical class 0.000 description 4
• 239000002246 antineoplastic agent Substances 0.000 description 4
• 230000008238 biochemical pathway Effects 0.000 description 4
• 210000004369 blood Anatomy 0.000 description 4
• 239000008280 blood Substances 0.000 description 4
• 230000036952 cancer formation Effects 0.000 description 4
• 231100000504 carcinogenesis Toxicity 0.000 description 4
• 230000001413 cellular effect Effects 0.000 description 4
• 230000006806 disease prevention Effects 0.000 description 4
• 230000004927 fusion Effects 0.000 description 4
• 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 4
• 102000034356 gene-regulatory proteins Human genes 0.000 description 4
• 108091006104 gene-regulatory proteins Proteins 0.000 description 4
• 230000002068 genetic effect Effects 0.000 description 4
• 210000004602 germ cell Anatomy 0.000 description 4
• 238000001727 in vivo Methods 0.000 description 4
• 210000004072 lung Anatomy 0.000 description 4
• 230000002071 myeloproliferative effect Effects 0.000 description 4
• 201000002528 pancreatic cancer Diseases 0.000 description 4
• 208000008443 pancreatic carcinoma Diseases 0.000 description 4
• 230000007170 pathology Effects 0.000 description 4
• 230000008707 rearrangement Effects 0.000 description 4
• 102200048955 rs121434569 Human genes 0.000 description 4
• 230000014616 translation Effects 0.000 description 4
• 230000005747 tumor angiogenesis Effects 0.000 description 4
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
• 102100026630 Aurora kinase C Human genes 0.000 description 3
• 108090000805 Aurora kinase C Proteins 0.000 description 3
• 102000015735 Beta-catenin Human genes 0.000 description 3
• 108060000903 Beta-catenin Proteins 0.000 description 3
• 206010005003 Bladder cancer Diseases 0.000 description 3
• 208000004860 Blast Crisis Diseases 0.000 description 3
• 101100005789 Caenorhabditis elegans cdk-4 gene Proteins 0.000 description 3
• 101150053721 Cdk5 gene Proteins 0.000 description 3
• 230000004544 DNA amplification Effects 0.000 description 3
• 239000012623 DNA damaging agent Substances 0.000 description 3
• 102400001368 Epidermal growth factor Human genes 0.000 description 3
• 101800003838 Epidermal growth factor Proteins 0.000 description 3
• 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 3
• 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 3
• 208000032612 Glial tumor Diseases 0.000 description 3
• 206010018338 Glioma Diseases 0.000 description 3
• 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 3
• 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 3
• 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 3
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 3
• 206010025323 Lymphomas Diseases 0.000 description 3
• 108091054455 MAP kinase family Proteins 0.000 description 3
• 102000043136 MAP kinase family Human genes 0.000 description 3
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
• 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 3
• 206010061535 Ovarian neoplasm Diseases 0.000 description 3
• 102400001093 PAK-2p27 Human genes 0.000 description 3
• 102000009572 RNA Polymerase II Human genes 0.000 description 3
• 108010009460 RNA Polymerase II Proteins 0.000 description 3
• 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 3
• 102100022828 Retinoblastoma-like protein 2 Human genes 0.000 description 3
• 108050002651 Retinoblastoma-like protein 2 Proteins 0.000 description 3
• 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 3
• 230000001594 aberrant effect Effects 0.000 description 3
• 230000002411 adverse Effects 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• 206010003246 arthritis Diseases 0.000 description 3
• 239000003719 aurora kinase inhibitor Substances 0.000 description 3
• 230000009286 beneficial effect Effects 0.000 description 3
• 125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 description 3
• 210000004204 blood vessel Anatomy 0.000 description 3
• 101150059448 cdk7 gene Proteins 0.000 description 3
• 230000025084 cell cycle arrest Effects 0.000 description 3
• 230000003915 cell function Effects 0.000 description 3
• 230000036755 cellular response Effects 0.000 description 3
• 210000003793 centrosome Anatomy 0.000 description 3
• 210000001072 colon Anatomy 0.000 description 3
• 208000029742 colonic neoplasm Diseases 0.000 description 3
• 230000006552 constitutive activation Effects 0.000 description 3
• 230000002596 correlated effect Effects 0.000 description 3
• 230000000875 corresponding effect Effects 0.000 description 3
• 230000001086 cytosolic effect Effects 0.000 description 3
• 230000006378 damage Effects 0.000 description 3
• 230000007547 defect Effects 0.000 description 3
• 230000030609 dephosphorylation Effects 0.000 description 3
• 238000006209 dephosphorylation reaction Methods 0.000 description 3
• 230000003831 deregulation Effects 0.000 description 3
• 206010012601 diabetes mellitus Diseases 0.000 description 3
• 229940116977 epidermal growth factor Drugs 0.000 description 3
• 210000002950 fibroblast Anatomy 0.000 description 3
• 230000004761 fibrosis Effects 0.000 description 3
• 230000003176 fibrotic effect Effects 0.000 description 3
• 230000006951 hyperphosphorylation Effects 0.000 description 3
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 3
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 3
• 230000011278 mitosis Effects 0.000 description 3
• 230000000394 mitotic effect Effects 0.000 description 3
• 230000004770 neurodegeneration Effects 0.000 description 3
• 208000002154 non-small cell lung carcinoma Diseases 0.000 description 3
• 210000001672 ovary Anatomy 0.000 description 3
• 210000000496 pancreas Anatomy 0.000 description 3
• 238000010837 poor prognosis Methods 0.000 description 3
• 210000002307 prostate Anatomy 0.000 description 3
• 208000005069 pulmonary fibrosis Diseases 0.000 description 3
• 230000022983 regulation of cell cycle Effects 0.000 description 3
• 230000001105 regulatory effect Effects 0.000 description 3
• 230000010076 replication Effects 0.000 description 3
• 230000005945 translocation Effects 0.000 description 3
• 230000005748 tumor development Effects 0.000 description 3
• 235000002374 tyrosine Nutrition 0.000 description 3
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 3
• 210000003932 urinary bladder Anatomy 0.000 description 3
• 210000005166 vasculature Anatomy 0.000 description 3
• 230000029663 wound healing Effects 0.000 description 3
• 108010012196 90-kDa Ribosomal Protein S6 Kinases Proteins 0.000 description 2
• 102000019050 90-kDa Ribosomal Protein S6 Kinases Human genes 0.000 description 2
• 206010000830 Acute leukaemia Diseases 0.000 description 2
• 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 2
• 102100032306 Aurora kinase B Human genes 0.000 description 2
• 101150035324 CDK9 gene Proteins 0.000 description 2
• 102000003952 Caspase 3 Human genes 0.000 description 2
• 108090000397 Caspase 3 Proteins 0.000 description 2
• 101150090188 Cdk8 gene Proteins 0.000 description 2
• 108010019244 Checkpoint Kinase 1 Proteins 0.000 description 2
• 102000006459 Checkpoint Kinase 1 Human genes 0.000 description 2
• 108010019243 Checkpoint Kinase 2 Proteins 0.000 description 2
• 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 2
• 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 2
• 102000002435 Cyclin T Human genes 0.000 description 2
• 108010068106 Cyclin T Proteins 0.000 description 2
• 230000012746 DNA damage checkpoint Effects 0.000 description 2
• 206010061818 Disease progression Diseases 0.000 description 2
• 206010059866 Drug resistance Diseases 0.000 description 2
• 208000005431 Endometrioid Carcinoma Diseases 0.000 description 2
• 108010055196 EphA2 Receptor Proteins 0.000 description 2
• 108010055191 EphA3 Receptor Proteins 0.000 description 2
• 108010055179 EphA4 Receptor Proteins 0.000 description 2
• 108010055182 EphA5 Receptor Proteins 0.000 description 2
• 102100030322 Ephrin type-A receptor 1 Human genes 0.000 description 2
• 102100030340 Ephrin type-A receptor 2 Human genes 0.000 description 2
• 102100030324 Ephrin type-A receptor 3 Human genes 0.000 description 2
• 102100021616 Ephrin type-A receptor 4 Human genes 0.000 description 2
• 102100021605 Ephrin type-A receptor 5 Human genes 0.000 description 2
• 102100023721 Ephrin-B2 Human genes 0.000 description 2
• 108010044090 Ephrin-B2 Proteins 0.000 description 2
• 102000003951 Erythropoietin Human genes 0.000 description 2
• 108090000394 Erythropoietin Proteins 0.000 description 2
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
• 108010074860 Factor Xa Proteins 0.000 description 2
• 230000010337 G2 phase Effects 0.000 description 2
• 208000034951 Genetic Translocation Diseases 0.000 description 2
• 102000009465 Growth Factor Receptors Human genes 0.000 description 2
• 108010009202 Growth Factor Receptors Proteins 0.000 description 2
• 206010019196 Head injury Diseases 0.000 description 2
• 108010033040 Histones Proteins 0.000 description 2
• 101000798300 Homo sapiens Aurora kinase A Proteins 0.000 description 2
• 101000938354 Homo sapiens Ephrin type-A receptor 1 Proteins 0.000 description 2
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
• 101000823316 Homo sapiens Tyrosine-protein kinase ABL1 Proteins 0.000 description 2
• 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
• 206010020751 Hypersensitivity Diseases 0.000 description 2
• 102000003746 Insulin Receptor Human genes 0.000 description 2
• 108010001127 Insulin Receptor Proteins 0.000 description 2
• 102000042838 JAK family Human genes 0.000 description 2
• 108091082332 JAK family Proteins 0.000 description 2
• 230000004163 JAK-STAT signaling pathway Effects 0.000 description 2
• 206010023249 Juvenile chronic myelomonocytic leukaemia Diseases 0.000 description 2
• 102100020880 Kit ligand Human genes 0.000 description 2
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
• 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
• 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
• 241000699670 Mus sp. Species 0.000 description 2
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
• 206010029260 Neuroblastoma Diseases 0.000 description 2
• BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 2
• 102000043276 Oncogene Human genes 0.000 description 2
• 206010033128 Ovarian cancer Diseases 0.000 description 2
• 229910019142 PO4 Inorganic materials 0.000 description 2
• 101150096038 PTH1R gene Proteins 0.000 description 2
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
• 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 2
• 101710148465 Platelet-derived growth factor receptor alpha Proteins 0.000 description 2
• 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 description 2
• 102000019014 Positive Transcriptional Elongation Factor B Human genes 0.000 description 2
• 108010012271 Positive Transcriptional Elongation Factor B Proteins 0.000 description 2
• 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
• 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 2
• 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 2
• 101710149951 Protein Tat Proteins 0.000 description 2
• 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 2
• 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 2
• 108010034782 Ribosomal Protein S6 Kinases Proteins 0.000 description 2
• 102000009738 Ribosomal Protein S6 Kinases Human genes 0.000 description 2
• 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 2
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
• 108010039445 Stem Cell Factor Proteins 0.000 description 2
• 208000006011 Stroke Diseases 0.000 description 2
• 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
• 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
• 208000033781 Thyroid carcinoma Diseases 0.000 description 2
• 102100023132 Transcription factor Jun Human genes 0.000 description 2
• 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
• 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
• 102100040247 Tumor necrosis factor Human genes 0.000 description 2
• 102100033254 Tumor suppressor ARF Human genes 0.000 description 2
• 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 description 2
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
• 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 2
• 102000013814 Wnt Human genes 0.000 description 2
• 108050003627 Wnt Proteins 0.000 description 2
• 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 2
• 108700025690 abl Genes Proteins 0.000 description 2
• 230000001154 acute effect Effects 0.000 description 2
• 238000007792 addition Methods 0.000 description 2
• 230000032683 aging Effects 0.000 description 2
• 208000026935 allergic disease Diseases 0.000 description 2
• 125000003275 alpha amino acid group Chemical group 0.000 description 2
• BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 2
• 229950010817 alvocidib Drugs 0.000 description 2
• 208000036878 aneuploidy Diseases 0.000 description 2
• 231100001075 aneuploidy Toxicity 0.000 description 2
• 239000002870 angiogenesis inducing agent Substances 0.000 description 2
• 239000004037 angiogenesis inhibitor Substances 0.000 description 2
• 229940121369 angiogenesis inhibitor Drugs 0.000 description 2
• 230000002491 angiogenic effect Effects 0.000 description 2
• 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 2
• 230000003305 autocrine Effects 0.000 description 2
• 230000035578 autophosphorylation Effects 0.000 description 2
• 230000006399 behavior Effects 0.000 description 2
• 210000004899 c-terminal region Anatomy 0.000 description 2
• 239000003560 cancer drug Substances 0.000 description 2
• 230000015556 catabolic process Effects 0.000 description 2
• 230000012820 cell cycle checkpoint Effects 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• 208000019065 cervical carcinoma Diseases 0.000 description 2
• 238000006243 chemical reaction Methods 0.000 description 2
• 210000004714 cranial suture Anatomy 0.000 description 2
• 231100000433 cytotoxic Toxicity 0.000 description 2
• 230000001472 cytotoxic effect Effects 0.000 description 2
• 230000007812 deficiency Effects 0.000 description 2
• 238000006731 degradation reaction Methods 0.000 description 2
• 238000012217 deletion Methods 0.000 description 2
• 230000037430 deletion Effects 0.000 description 2
• 230000008021 deposition Effects 0.000 description 2
• 230000002074 deregulated effect Effects 0.000 description 2
• 229950006137 dexfosfoserine Drugs 0.000 description 2
• 230000005750 disease progression Effects 0.000 description 2
• 230000013020 embryo development Effects 0.000 description 2
• 208000028730 endometrioid adenocarcinoma Diseases 0.000 description 2
• 238000005516 engineering process Methods 0.000 description 2
• 206010015037 epilepsy Diseases 0.000 description 2
• 210000000981 epithelium Anatomy 0.000 description 2
• 229940105423 erythropoietin Drugs 0.000 description 2
• 210000003238 esophagus Anatomy 0.000 description 2
• 229940011871 estrogen Drugs 0.000 description 2
• 239000000262 estrogen Substances 0.000 description 2
• 108700014844 flt3 ligand Proteins 0.000 description 2
• 210000003128 head Anatomy 0.000 description 2
• 150000002391 heterocyclic compounds Chemical class 0.000 description 2
• 229940088597 hormone Drugs 0.000 description 2
• 239000005556 hormone Substances 0.000 description 2
• 230000002779 inactivation Effects 0.000 description 2
• 230000001939 inductive effect Effects 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• 238000003780 insertion Methods 0.000 description 2
• 230000037431 insertion Effects 0.000 description 2
• 230000006362 insulin response pathway Effects 0.000 description 2
• 210000003734 kidney Anatomy 0.000 description 2
• 108020001756 ligand binding domains Proteins 0.000 description 2
• 210000004185 liver Anatomy 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 210000004379 membrane Anatomy 0.000 description 2
• 230000002297 mitogenic effect Effects 0.000 description 2
• 210000003739 neck Anatomy 0.000 description 2
• 208000015122 neurodegenerative disease Diseases 0.000 description 2
• 230000007823 neuropathy Effects 0.000 description 2
• 201000001119 neuropathy Diseases 0.000 description 2
• 230000002246 oncogenic effect Effects 0.000 description 2
• 230000011164 ossification Effects 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• 208000033808 peripheral neuropathy Diseases 0.000 description 2
• 239000010452 phosphate Substances 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
• 235000021317 phosphate Nutrition 0.000 description 2
• 230000000865 phosphorylative effect Effects 0.000 description 2
• BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 2
• USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 2
• 230000035790 physiological processes and functions Effects 0.000 description 2
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 2
• 230000000750 progressive effect Effects 0.000 description 2
• 201000001514 prostate carcinoma Diseases 0.000 description 2
• 239000003909 protein kinase inhibitor Substances 0.000 description 2
• 230000009822 protein phosphorylation Effects 0.000 description 2
• 230000035945 sensitivity Effects 0.000 description 2
• 108010022404 serum-glucocorticoid regulated kinase Proteins 0.000 description 2
• 238000009097 single-agent therapy Methods 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 230000000392 somatic effect Effects 0.000 description 2
• 108010087686 src-Family Kinases Proteins 0.000 description 2
• 102000009076 src-Family Kinases Human genes 0.000 description 2
• 230000035882 stress Effects 0.000 description 2
• 208000024891 symptom Diseases 0.000 description 2
• 238000003786 synthesis reaction Methods 0.000 description 2
• 208000013077 thyroid gland carcinoma Diseases 0.000 description 2
• 230000004565 tumor cell growth Effects 0.000 description 2
• 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 2
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
• 201000005112 urinary bladder cancer Diseases 0.000 description 2
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
• MHFUWOIXNMZFIW-WNQIDUERSA-N (2s)-2-hydroxypropanoic acid;n-[4-[4-(4-methylpiperazin-1-yl)-6-[(5-methyl-1h-pyrazol-3-yl)amino]pyrimidin-2-yl]sulfanylphenyl]cyclopropanecarboxamide Chemical compound C[C@H](O)C(O)=O.C1CN(C)CCN1C1=CC(NC2=NNC(C)=C2)=NC(SC=2C=CC(NC(=O)C3CC3)=CC=2)=N1 MHFUWOIXNMZFIW-WNQIDUERSA-N 0.000 description 1
• HKWJHKSHEWVOSS-OMDJCSNQSA-N 1,2-dihexadecanoyl-sn-glycero-3-phospho-(1D-myo-inositol-3,4-bisphosphate) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCC)COP(O)(=O)O[C@H]1[C@H](O)[C@@H](O)[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H]1O HKWJHKSHEWVOSS-OMDJCSNQSA-N 0.000 description 1
• QHHHLHCCVDMOJI-UHFFFAOYSA-N 1,3-thiazol-4-amine Chemical class NC1=CSC=N1 QHHHLHCCVDMOJI-UHFFFAOYSA-N 0.000 description 1
• GHFDYLOGYDGRHI-UHFFFAOYSA-N 1h-indeno[1,2-c]pyrazol-4-one Chemical class C12=CC=CC=C2C(=O)C2=C1NN=C2 GHFDYLOGYDGRHI-UHFFFAOYSA-N 0.000 description 1
• JWYUFVNJZUSCSM-UHFFFAOYSA-N 2-aminobenzimidazole Chemical class C1=CC=C2NC(N)=NC2=C1 JWYUFVNJZUSCSM-UHFFFAOYSA-N 0.000 description 1
• 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
• SCHVGFGBJWBMFU-UHFFFAOYSA-N 3-sulfonylpyrazolo[3,4-b]pyridine Chemical class C1=CC=C2C(=S(=O)=O)N=NC2=N1 SCHVGFGBJWBMFU-UHFFFAOYSA-N 0.000 description 1
• BNBKZIMPRGCPAO-UHFFFAOYSA-N 4-(1h-benzimidazol-2-yl)-1h-pyrazol-5-amine Chemical compound NC1=NNC=C1C1=NC2=CC=CC=C2N1 BNBKZIMPRGCPAO-UHFFFAOYSA-N 0.000 description 1
• 206010069754 Acquired gene mutation Diseases 0.000 description 1
• 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 description 1
• 206010001889 Alveolitis Diseases 0.000 description 1
• 208000024827 Alzheimer disease Diseases 0.000 description 1
• 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
• 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
• 101100067974 Arabidopsis thaliana POP2 gene Proteins 0.000 description 1
• 206010003591 Ataxia Diseases 0.000 description 1
• 201000001320 Atherosclerosis Diseases 0.000 description 1
• 208000023275 Autoimmune disease Diseases 0.000 description 1
• 208000003950 B-cell lymphoma Diseases 0.000 description 1
• 208000037398 BCR-ABL1 negative atypical chronic myeloid leukemia Diseases 0.000 description 1
• 101150049556 Bcr gene Proteins 0.000 description 1
• 201000004569 Blindness Diseases 0.000 description 1
• 102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 1
• 101710168309 CCAAT/enhancer-binding protein alpha Proteins 0.000 description 1
• 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
• 102000011727 Caspases Human genes 0.000 description 1
• 108010076667 Caspases Proteins 0.000 description 1
• 206010008479 Chest Pain Diseases 0.000 description 1
• 108091026890 Coding region Proteins 0.000 description 1
• 108020004705 Codon Proteins 0.000 description 1
• 102000008186 Collagen Human genes 0.000 description 1
• 108010035532 Collagen Proteins 0.000 description 1
• 206010010356 Congenital anomaly Diseases 0.000 description 1
• 206010011224 Cough Diseases 0.000 description 1
• 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 1
• 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 1
• 108010068192 Cyclin A Proteins 0.000 description 1
• 102000002428 Cyclin C Human genes 0.000 description 1
• 108010068155 Cyclin C Proteins 0.000 description 1
• 102000003910 Cyclin D Human genes 0.000 description 1
• 108090000259 Cyclin D Proteins 0.000 description 1
• 108010058546 Cyclin D1 Proteins 0.000 description 1
• 102000002495 Cyclin H Human genes 0.000 description 1
• 108010068237 Cyclin H Proteins 0.000 description 1
• 102100025191 Cyclin-A2 Human genes 0.000 description 1
• 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
• 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
• 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 1
• 102000013717 Cyclin-Dependent Kinase 5 Human genes 0.000 description 1
• 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 description 1
• 108010009392 Cyclin-Dependent Kinase Inhibitor p16 Proteins 0.000 description 1
• 108010016777 Cyclin-Dependent Kinase Inhibitor p27 Proteins 0.000 description 1
• 102000000577 Cyclin-Dependent Kinase Inhibitor p27 Human genes 0.000 description 1
• 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 1
• 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 1
• 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
• 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
• 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 description 1
• 102100034770 Cyclin-dependent kinase inhibitor 3 Human genes 0.000 description 1
• 102000010831 Cytoskeletal Proteins Human genes 0.000 description 1
• 108010037414 Cytoskeletal Proteins Proteins 0.000 description 1
• 102000053602 DNA Human genes 0.000 description 1
• 230000022963 DNA damage response, signal transduction by p53 class mediator Effects 0.000 description 1
• 230000004568 DNA-binding Effects 0.000 description 1
• 208000008334 Dermatofibrosarcoma Diseases 0.000 description 1
• 206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 description 1
• 208000010837 Diabetic eye disease Diseases 0.000 description 1
• 101001031598 Dictyostelium discoideum Probable serine/threonine-protein kinase fhkC Proteins 0.000 description 1
• 101100457919 Drosophila melanogaster stg gene Proteins 0.000 description 1
• 206010058314 Dysplasia Diseases 0.000 description 1
• 208000000059 Dyspnea Diseases 0.000 description 1
• 206010013975 Dyspnoeas Diseases 0.000 description 1
• 101150029707 ERBB2 gene Proteins 0.000 description 1
• 102000056118 Ephrin receptor family Human genes 0.000 description 1
• 102100030779 Ephrin type-B receptor 1 Human genes 0.000 description 1
• 102100031984 Ephrin type-B receptor 6 Human genes 0.000 description 1
• 101150021185 FGF gene Proteins 0.000 description 1
• 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
• 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
• 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
• 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
• 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
• 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
• 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 1
• 102100037362 Fibronectin Human genes 0.000 description 1
• 108010067306 Fibronectins Proteins 0.000 description 1
• 201000011240 Frontotemporal dementia Diseases 0.000 description 1
• 230000010190 G1 phase Effects 0.000 description 1
• 102100024165 G1/S-specific cyclin-D1 Human genes 0.000 description 1
• 206010061968 Gastric neoplasm Diseases 0.000 description 1
• 102100032863 General transcription factor IIH subunit 3 Human genes 0.000 description 1
• 206010018364 Glomerulonephritis Diseases 0.000 description 1
• 229920002527 Glycogen Polymers 0.000 description 1
• 102100021888 Helix-loop-helix protein 1 Human genes 0.000 description 1
• 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
• 102100033636 Histone H3.2 Human genes 0.000 description 1
• 241000282412 Homo Species 0.000 description 1
• 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
• 101000798306 Homo sapiens Aurora kinase B Proteins 0.000 description 1
• 101100118549 Homo sapiens EGFR gene Proteins 0.000 description 1
• 101001064150 Homo sapiens Ephrin type-B receptor 1 Proteins 0.000 description 1
• 101001064451 Homo sapiens Ephrin type-B receptor 6 Proteins 0.000 description 1
• 101100335080 Homo sapiens FLT3 gene Proteins 0.000 description 1
• 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 1
• 101000666405 Homo sapiens General transcription factor IIH subunit 1 Proteins 0.000 description 1
• 101000655398 Homo sapiens General transcription factor IIH subunit 2 Proteins 0.000 description 1
• 101000655391 Homo sapiens General transcription factor IIH subunit 3 Proteins 0.000 description 1
• 101000655406 Homo sapiens General transcription factor IIH subunit 4 Proteins 0.000 description 1
• 101000655402 Homo sapiens General transcription factor IIH subunit 5 Proteins 0.000 description 1
• 101000897691 Homo sapiens Helix-loop-helix protein 1 Proteins 0.000 description 1
• 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
• 101100520968 Homo sapiens PPP1R1B gene Proteins 0.000 description 1
• 101000610537 Homo sapiens Prokineticin-1 Proteins 0.000 description 1
• 101000603402 Homo sapiens Protein NPAT Proteins 0.000 description 1
• 101000573199 Homo sapiens Protein PML Proteins 0.000 description 1
• 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 description 1
• 101000798015 Homo sapiens RAC-beta serine/threonine-protein kinase Proteins 0.000 description 1
• 101001092185 Homo sapiens Regulator of cell cycle RGCC Proteins 0.000 description 1
• 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 1
• 101001129076 Homo sapiens Serine/threonine-protein kinase N1 Proteins 0.000 description 1
• 101000617830 Homo sapiens Sterol O-acyltransferase 1 Proteins 0.000 description 1
• 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
• 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
• 206010021143 Hypoxia Diseases 0.000 description 1
• 241000692870 Inachis io Species 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102000004310 Ion Channels Human genes 0.000 description 1
• 108090000862 Ion Channels Proteins 0.000 description 1
• 206010072206 Janus kinase 2 mutation Diseases 0.000 description 1
• 208000008839 Kidney Neoplasms Diseases 0.000 description 1
• 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 1
• 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
• 208000000265 Lobular Carcinoma Diseases 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• 208000000172 Medulloblastoma Diseases 0.000 description 1
• 101710115937 Microtubule-associated protein tau Proteins 0.000 description 1
• 206010073149 Multiple endocrine neoplasia Type 2 Diseases 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
• 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
• 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 description 1
• 101150092630 Myt1 gene Proteins 0.000 description 1
• BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
• 206010029098 Neoplasm skin Diseases 0.000 description 1
• 102000007999 Nuclear Proteins Human genes 0.000 description 1
• 108010089610 Nuclear Proteins Proteins 0.000 description 1
• 102100034404 Nuclear factor of activated T-cells, cytoplasmic 1 Human genes 0.000 description 1
• 101710151542 Nuclear factor of activated T-cells, cytoplasmic 1 Proteins 0.000 description 1
• 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
• 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
• 108010001441 Phosphopeptides Proteins 0.000 description 1
• 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
• 102000010995 Pleckstrin homology domains Human genes 0.000 description 1
• 108050001185 Pleckstrin homology domains Proteins 0.000 description 1
• 101150016155 Pml gene Proteins 0.000 description 1
• 208000008601 Polycythemia Diseases 0.000 description 1
• 206010057846 Primitive neuroectodermal tumour Diseases 0.000 description 1
• 108010029485 Protein Isoforms Proteins 0.000 description 1
• 102000001708 Protein Isoforms Human genes 0.000 description 1
• 108090000315 Protein Kinase C Proteins 0.000 description 1
• 102000003923 Protein Kinase C Human genes 0.000 description 1
• 102100038870 Protein NPAT Human genes 0.000 description 1
• 102100026375 Protein PML Human genes 0.000 description 1
• 102100024556 Protein phosphatase 1 regulatory subunit 1B Human genes 0.000 description 1
• 108010045292 Proto-Oncogene Proteins c-abl Proteins 0.000 description 1
• 102000005663 Proto-Oncogene Proteins c-abl Human genes 0.000 description 1
• 201000004681 Psoriasis Diseases 0.000 description 1
• 102100032315 RAC-beta serine/threonine-protein kinase Human genes 0.000 description 1
• 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
• 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
• 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
• 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
• 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
• 102100035542 Regulator of cell cycle RGCC Human genes 0.000 description 1
• 206010038389 Renal cancer Diseases 0.000 description 1
• 108091027981 Response element Proteins 0.000 description 1
• 108050002653 Retinoblastoma protein Proteins 0.000 description 1
• 101150112625 SSN3 gene Proteins 0.000 description 1
• 101100123851 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HER1 gene Proteins 0.000 description 1
• 101100150415 Schizosaccharomyces pombe (strain 972 / ATCC 24843) srb10 gene Proteins 0.000 description 1
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
• 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 1
• 102100031206 Serine/threonine-protein kinase N1 Human genes 0.000 description 1
• 108020004682 Single-Stranded DNA Proteins 0.000 description 1
• 208000000453 Skin Neoplasms Diseases 0.000 description 1
• 108020004459 Small interfering RNA Proteins 0.000 description 1
• 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
• 102100021993 Sterol O-acyltransferase 1 Human genes 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• 101000697584 Streptomyces lavendulae Streptothricin acetyltransferase Proteins 0.000 description 1
• 102000017299 Synapsin-1 Human genes 0.000 description 1
• 108050005241 Synapsin-1 Proteins 0.000 description 1
• 102000013265 Syntaxin 1 Human genes 0.000 description 1
• 108010090618 Syntaxin 1 Proteins 0.000 description 1
• 210000001744 T-lymphocyte Anatomy 0.000 description 1
• 229940122388 Thrombin inhibitor Drugs 0.000 description 1
• 102000036693 Thrombopoietin Human genes 0.000 description 1
• 108010041111 Thrombopoietin Proteins 0.000 description 1
• 108050007918 Transcription factor STAT Proteins 0.000 description 1
• 102000000887 Transcription factor STAT Human genes 0.000 description 1
• 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
• 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
• 102000015098 Tumor Suppressor Protein p53 Human genes 0.000 description 1
• 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
• 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
• 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
• 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 1
• 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
• 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
• 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 1
• 208000032594 Vascular Remodeling Diseases 0.000 description 1
• 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 1
• 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
• 208000036142 Viral infection Diseases 0.000 description 1
• 230000004156 Wnt signaling pathway Effects 0.000 description 1
• 101100102932 Xenopus laevis wee2-b gene Proteins 0.000 description 1
• RQQIRMLGKSPXSE-WIPMOJCBSA-N [1-acetyloxy-2-[[(2s,3r,5s,6s)-2,6-dihydroxy-3,4,5-triphosphonooxycyclohexyl]oxy-hydroxyphosphoryl]oxyethyl] acetate Chemical compound CC(=O)OC(OC(C)=O)COP(O)(=O)OC1[C@H](O)[C@H](OP(O)(O)=O)C(OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H]1O RQQIRMLGKSPXSE-WIPMOJCBSA-N 0.000 description 1
• KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 description 1
• 230000035508 accumulation Effects 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 description 1
• 210000004712 air sac Anatomy 0.000 description 1
• 230000007815 allergy Effects 0.000 description 1
• 230000006427 angiogenic response Effects 0.000 description 1
• 238000010171 animal model Methods 0.000 description 1
• 230000000840 anti-viral effect Effects 0.000 description 1
• 239000003146 anticoagulant agent Substances 0.000 description 1
• 229940127219 anticoagulant drug Drugs 0.000 description 1
• 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 1
• 239000000074 antisense oligonucleotide Substances 0.000 description 1
• 238000012230 antisense oligonucleotides Methods 0.000 description 1
• 230000004596 appetite loss Effects 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• 210000004618 arterial endothelial cell Anatomy 0.000 description 1
• 208000006673 asthma Diseases 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 201000004892 atypical chronic myeloid leukemia Diseases 0.000 description 1
• 210000004227 basal ganglia Anatomy 0.000 description 1
• 230000002457 bidirectional effect Effects 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 102000023732 binding proteins Human genes 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 230000003851 biochemical process Effects 0.000 description 1
• 230000008827 biological function Effects 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 239000000090 biomarker Substances 0.000 description 1
• 201000001531 bladder carcinoma Diseases 0.000 description 1
• 230000000903 blocking effect Effects 0.000 description 1
• 210000000988 bone and bone Anatomy 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 210000002798 bone marrow cell Anatomy 0.000 description 1
• 201000003714 breast lobular carcinoma Diseases 0.000 description 1
• 239000011575 calcium Substances 0.000 description 1
• 230000009702 cancer cell proliferation Effects 0.000 description 1
• 230000000711 cancerogenic effect Effects 0.000 description 1
• 210000000845 cartilage Anatomy 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 108020001778 catalytic domains Proteins 0.000 description 1
• 230000003197 catalytic effect Effects 0.000 description 1
• 108010046616 cdc25 Phosphatases Proteins 0.000 description 1
• 102000007588 cdc25 Phosphatases Human genes 0.000 description 1
• 101150069072 cdc25 gene Proteins 0.000 description 1
• 230000020411 cell activation Effects 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 230000034303 cell budding Effects 0.000 description 1
• 230000006369 cell cycle progression Effects 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000009087 cell motility Effects 0.000 description 1
• 230000010307 cell transformation Effects 0.000 description 1
• 230000030570 cellular localization Effects 0.000 description 1
• 210000003169 central nervous system Anatomy 0.000 description 1
• 208000015114 central nervous system disease Diseases 0.000 description 1
• 210000001638 cerebellum Anatomy 0.000 description 1
• 210000003679 cervix uteri Anatomy 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 230000000973 chemotherapeutic effect Effects 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 201000002797 childhood leukemia Diseases 0.000 description 1
• 230000002759 chromosomal effect Effects 0.000 description 1
• 230000024321 chromosome segregation Effects 0.000 description 1
• 230000007882 cirrhosis Effects 0.000 description 1
• 208000019425 cirrhosis of liver Diseases 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 230000007012 clinical effect Effects 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 229920001436 collagen Polymers 0.000 description 1
• 230000002860 competitive effect Effects 0.000 description 1
• 230000001276 controlling effect Effects 0.000 description 1
• 230000001054 cortical effect Effects 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 230000002559 cytogenic effect Effects 0.000 description 1
• 102000003675 cytokine receptors Human genes 0.000 description 1
• 108010057085 cytokine receptors Proteins 0.000 description 1
• 230000021953 cytokinesis Effects 0.000 description 1
• 229940127089 cytotoxic agent Drugs 0.000 description 1
• 230000003013 cytotoxicity Effects 0.000 description 1
• 231100000135 cytotoxicity Toxicity 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 230000000593 degrading effect Effects 0.000 description 1
• 230000001934 delay Effects 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 238000000113 differential scanning calorimetry Methods 0.000 description 1
• 230000001079 digestive effect Effects 0.000 description 1
• 238000006471 dimerization reaction Methods 0.000 description 1
• 230000009266 disease activity Effects 0.000 description 1
• 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
• 230000005782 double-strand break Effects 0.000 description 1
• 230000003828 downregulation Effects 0.000 description 1
• 208000017574 dry cough Diseases 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 230000008011 embryonic death Effects 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 230000010595 endothelial cell migration Effects 0.000 description 1
• 210000000105 enteric nervous system Anatomy 0.000 description 1
• 230000029578 entry into host Effects 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 230000002327 eosinophilic effect Effects 0.000 description 1
• 230000010437 erythropoiesis Effects 0.000 description 1
• 102000015694 estrogen receptors Human genes 0.000 description 1
• 108010038795 estrogen receptors Proteins 0.000 description 1
• 210000003527 eukaryotic cell Anatomy 0.000 description 1
• 230000003492 excitotoxic effect Effects 0.000 description 1
• 231100000063 excitotoxicity Toxicity 0.000 description 1
• 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 230000008622 extracellular signaling Effects 0.000 description 1
• 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
• 206010016256 fatigue Diseases 0.000 description 1
• 230000003352 fibrogenic effect Effects 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• 206010017758 gastric cancer Diseases 0.000 description 1
• 230000002496 gastric effect Effects 0.000 description 1
• 230000007614 genetic variation Effects 0.000 description 1
• 229940096919 glycogen Drugs 0.000 description 1
• 230000003394 haemopoietic effect Effects 0.000 description 1
• 208000014951 hematologic disease Diseases 0.000 description 1
• 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
• 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
• 208000021173 high grade B-cell lymphoma Diseases 0.000 description 1
• 210000005260 human cell Anatomy 0.000 description 1
• 235000020256 human milk Nutrition 0.000 description 1
• 210000004251 human milk Anatomy 0.000 description 1
• 230000009610 hypersensitivity Effects 0.000 description 1
• 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
• 230000007954 hypoxia Effects 0.000 description 1
• 208000026278 immune system disease Diseases 0.000 description 1
• 230000000415 inactivating effect Effects 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 230000006698 induction Effects 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000004054 inflammatory process Effects 0.000 description 1
• 238000011221 initial treatment Methods 0.000 description 1
• 230000030214 innervation Effects 0.000 description 1
• 102000006495 integrins Human genes 0.000 description 1
• 108010044426 integrins Proteins 0.000 description 1
• 230000008611 intercellular interaction Effects 0.000 description 1
• 230000016507 interphase Effects 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 230000032631 intramembranous ossification Effects 0.000 description 1
• 230000009545 invasion Effects 0.000 description 1
• 206010073095 invasive ductal breast carcinoma Diseases 0.000 description 1
• 206010073096 invasive lobular breast carcinoma Diseases 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• GURKHSYORGJETM-WAQYZQTGSA-N irinotecan hydrochloride (anhydrous) Chemical compound Cl.C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 GURKHSYORGJETM-WAQYZQTGSA-N 0.000 description 1
• 230000002427 irreversible effect Effects 0.000 description 1
• 208000028867 ischemia Diseases 0.000 description 1
• 201000010982 kidney cancer Diseases 0.000 description 1
• 150000003893 lactate salts Chemical class 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 201000007270 liver cancer Diseases 0.000 description 1
• 208000014018 liver neoplasm Diseases 0.000 description 1
• 208000019017 loss of appetite Diseases 0.000 description 1
• 235000021266 loss of appetite Nutrition 0.000 description 1
• 230000004777 loss-of-function mutation Effects 0.000 description 1
• 210000003750 lower gastrointestinal tract Anatomy 0.000 description 1
• 201000005202 lung cancer Diseases 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 210000002751 lymph Anatomy 0.000 description 1
• 210000001165 lymph node Anatomy 0.000 description 1
• 210000004698 lymphocyte Anatomy 0.000 description 1
• 210000003738 lymphoid progenitor cell Anatomy 0.000 description 1
• 230000036244 malformation Effects 0.000 description 1
• 208000026037 malignant tumor of neck Diseases 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 201000001441 melanoma Diseases 0.000 description 1
• 230000005906 menstruation Effects 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• SYMRCBYIJZXNNX-UHFFFAOYSA-N methanesulfonic acid;n-phenylbenzamide Chemical compound CS(O)(=O)=O.C=1C=CC=CC=1C(=O)NC1=CC=CC=C1 SYMRCBYIJZXNNX-UHFFFAOYSA-N 0.000 description 1
• 230000008880 microtubule cytoskeleton organization Effects 0.000 description 1
• 230000005012 migration Effects 0.000 description 1
• 238000013508 migration Methods 0.000 description 1
• 239000003226 mitogen Substances 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 230000006618 mitotic catastrophe Effects 0.000 description 1
• 230000017205 mitotic cell cycle checkpoint Effects 0.000 description 1
• 210000000479 mitotic spindle apparatus Anatomy 0.000 description 1
• 230000009456 molecular mechanism Effects 0.000 description 1
• 239000002062 molecular scaffold Substances 0.000 description 1
• 210000001616 monocyte Anatomy 0.000 description 1
• 230000004899 motility Effects 0.000 description 1
• 210000004877 mucosa Anatomy 0.000 description 1
• 210000003205 muscle Anatomy 0.000 description 1
• 239000003471 mutagenic agent Substances 0.000 description 1
• 231100000707 mutagenic chemical Toxicity 0.000 description 1
• 230000003505 mutagenic effect Effects 0.000 description 1
• 230000007886 mutagenicity Effects 0.000 description 1
• 231100000299 mutagenicity Toxicity 0.000 description 1
• 210000000066 myeloid cell Anatomy 0.000 description 1
• 208000025113 myeloid leukemia Diseases 0.000 description 1
• 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
• 230000009826 neoplastic cell growth Effects 0.000 description 1
• 210000005036 nerve Anatomy 0.000 description 1
• 230000000626 neurodegenerative effect Effects 0.000 description 1
• 230000007472 neurodevelopment Effects 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000009223 neuronal apoptosis Effects 0.000 description 1
• 230000006764 neuronal dysfunction Effects 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 230000005937 nuclear translocation Effects 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 235000016709 nutrition Nutrition 0.000 description 1
• 238000006384 oligomerization reaction Methods 0.000 description 1
• 231100000590 oncogenic Toxicity 0.000 description 1
• 230000000771 oncological effect Effects 0.000 description 1
• 238000011275 oncology therapy Methods 0.000 description 1
• 108091008819 oncoproteins Proteins 0.000 description 1
• 201000002740 oral squamous cell carcinoma Diseases 0.000 description 1
• 210000000056 organ Anatomy 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 210000000963 osteoblast Anatomy 0.000 description 1
• 230000002188 osteogenic effect Effects 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 230000016087 ovulation Effects 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 201000010198 papillary carcinoma Diseases 0.000 description 1
• 230000003076 paracrine Effects 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 230000007310 pathophysiology Effects 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 210000001428 peripheral nervous system Anatomy 0.000 description 1
• 238000009520 phase I clinical trial Methods 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
• 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
• 229960003073 pirfenidone Drugs 0.000 description 1
• ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 1
• 102000054765 polymorphisms of proteins Human genes 0.000 description 1
• 239000002157 polynucleotide Substances 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 230000002028 premature Effects 0.000 description 1
• 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
• 230000000861 pro-apoptotic effect Effects 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
• 230000000069 prophylactic effect Effects 0.000 description 1
• 208000023958 prostate neoplasm Diseases 0.000 description 1
• 239000003528 protein farnesyltransferase inhibitor Substances 0.000 description 1
• 229940121649 protein inhibitor Drugs 0.000 description 1
• 239000012268 protein inhibitor Substances 0.000 description 1
• 238000001243 protein synthesis Methods 0.000 description 1
• 230000004850 protein–protein interaction Effects 0.000 description 1
• 101150103120 ptc gene Proteins 0.000 description 1
• 150000003212 purines Chemical class 0.000 description 1
• 238000001959 radiotherapy Methods 0.000 description 1
• 102000016914 ras Proteins Human genes 0.000 description 1
• 230000006798 recombination Effects 0.000 description 1
• 238000005215 recombination Methods 0.000 description 1
• 230000007115 recruitment Effects 0.000 description 1
• 230000008844 regulatory mechanism Effects 0.000 description 1
• 230000007363 regulatory process Effects 0.000 description 1
• 230000008439 repair process Effects 0.000 description 1
• 230000028617 response to DNA damage stimulus Effects 0.000 description 1
• 210000001525 retina Anatomy 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• 210000003705 ribosome Anatomy 0.000 description 1
• 102200143304 rs351855 Human genes 0.000 description 1
• 210000004761 scalp Anatomy 0.000 description 1
• 201000000980 schizophrenia Diseases 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 208000011581 secondary neoplasm Diseases 0.000 description 1
• 230000028327 secretion Effects 0.000 description 1
• 238000005204 segregation Methods 0.000 description 1
• 239000000849 selective androgen receptor modulator Substances 0.000 description 1
• BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 1
• 230000001568 sexual effect Effects 0.000 description 1
• 230000035939 shock Effects 0.000 description 1
• 208000013220 shortness of breath Diseases 0.000 description 1
• 102000034285 signal transducing proteins Human genes 0.000 description 1
• 108091006024 signal transducing proteins Proteins 0.000 description 1
• 208000000587 small cell lung carcinoma Diseases 0.000 description 1
• 230000037439 somatic mutation Effects 0.000 description 1
• IVDHYUQIDRJSTI-UHFFFAOYSA-N sorafenib tosylate Chemical compound [H+].CC1=CC=C(S([O-])(=O)=O)C=C1.C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 IVDHYUQIDRJSTI-UHFFFAOYSA-N 0.000 description 1
• 241000894007 species Species 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 230000007046 spindle assembly involved in mitosis Effects 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 239000003270 steroid hormone Substances 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 201000011549 stomach cancer Diseases 0.000 description 1
• 238000006467 substitution reaction Methods 0.000 description 1
• 230000009885 systemic effect Effects 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• 210000001550 testis Anatomy 0.000 description 1
• ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 239000003868 thrombin inhibitor Substances 0.000 description 1
• 230000009424 thromboembolic effect Effects 0.000 description 1
• 210000001541 thymus gland Anatomy 0.000 description 1
• 210000001685 thyroid gland Anatomy 0.000 description 1
• 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• 230000001131 transforming effect Effects 0.000 description 1
• 238000013519 translation Methods 0.000 description 1
• 230000014621 translational initiation Effects 0.000 description 1
• 102000027257 transmembrane receptors Human genes 0.000 description 1
• 108091008578 transmembrane receptors Proteins 0.000 description 1
• 230000001960 triggered effect Effects 0.000 description 1
• 108010036927 trypsin-like serine protease Proteins 0.000 description 1
• 210000005239 tubule Anatomy 0.000 description 1
• 231100000588 tumorigenic Toxicity 0.000 description 1
• 230000000381 tumorigenic effect Effects 0.000 description 1
• 230000007306 turnover Effects 0.000 description 1
• 150000003668 tyrosines Chemical class 0.000 description 1
• 230000002620 ureteric effect Effects 0.000 description 1
• 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 150000003679 valine derivatives Chemical class 0.000 description 1
• 230000002792 vascular Effects 0.000 description 1
• 230000006459 vascular development Effects 0.000 description 1
• 230000000304 vasodilatating effect Effects 0.000 description 1
• 229940124549 vasodilator Drugs 0.000 description 1
• 239000003071 vasodilator agent Substances 0.000 description 1
• 230000007998 vessel formation Effects 0.000 description 1
• 230000009385 viral infection Effects 0.000 description 1
• 230000003612 virological effect Effects 0.000 description 1
• 230000004580 weight loss Effects 0.000 description 1